Form 10-Q PMV Pharmaceuticals, For: Sep 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Axsome Therapeutics (AXSM) PT Raised to $380 at Jefferies
Oppenheimer Upgrades PMV Pharmaceuticals Inc. (PMVP) to Outperform
November 8, 2024 6:04 AM ESTOppenheimer analyst Jeff Jones upgraded PMV Pharmaceuticals Inc. (NASDAQ: PMVP) from Perform to Outperform with a price target of $6.00.
The analyst comments "On Thursday, PMV Pharmaceuticals reported 3Q results and provided a business update. The Phase 2/pivotal monotherapy trial for rezatapopt remains on... More
